- Home
- IMMX vs ASRT Comparison
IMMX vs ASRT Comparison
Compare IMMX & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMMX | ASRT |
|---|---|---|
| Founded | 2014 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.6M | 75.1M |
| IPO Year | 2021 | 1997 |
Fundamental Metrics
Financial Performance| Metric | IMMX | ASRT |
|---|---|---|
| Price | $7.01 | $0.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | $3.00 |
| AVG Volume (30 Days) | ★ 1.3M | 438.8K |
| Earning Date | 11-07-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $137,354,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 9.22 |
| 52 Week Low | $1.34 | $0.51 |
| 52 Week High | $7.73 | $1.01 |
Technical Indicators
Market Signals| Indicator | IMMX | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 79.16 | 47.26 |
| Support Level | $4.50 | $0.75 |
| Resistance Level | $4.48 | $0.80 |
| Average True Range (ATR) | 0.62 | 0.04 |
| MACD | 0.28 | 0.01 |
| Stochastic Oscillator | 83.29 | 74.57 |
Price Performance
Historical ComparisonAbout IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.